Hypertrophic cardiomyopathies
LXRXLexicon Pharmaceuticals IncCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for ZYNQUISTA™ (sotagliflozin) in Hypertrophic cardiomyopathies . The expected timing is based on the latest available company guidance and may change.
SONATA-HCM trial. 8/3/24- Trial initiated w/ multiple sites open for recruitment. 8/6/25- Enrollment underway. 11/06/25:- All 130 SONATA-HCM sites across 20 countries have been initiated and enrollment is accelerating in the 500-patient Ph3 study; enrollment completion remains on track for 2026. 03/05/26:- SONATA-HCM surpassed 50% enrollment; enrollment completion expected Mid-2026; topline Ph3 results expected in Q1 2027. 05/07/26:- SONATA-HCM enrollment continues; company reiterates Mid-2026 enrollment completion and Q1 2027 topline Ph3 results. 07/27/26:- Ph3 SONATA-HCM enrollment completed; study exceeded 500 patients. Topline results anticipated Q1 2027. 08/06/26:- SONATA-HCM enrollment completed. Topline Ph3 results remain expected Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.